Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy
Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L
Published in Journal of Clinical Oncology
Key Findings
Acetyl-L-carnitine did not prevent taxane-induced peripheral neuropathy and was associated with worse neuropathy scores than placebo at 24 weeks.
Conclusions
Acetyl-L-carnitine should not be used to prevent chemotherapy-induced numbness and tingling.
Supplements Studied
Acetyl-L-carnitine was inferior to placebo in the prevention of chemotherapy-induced peripheral neuropathy.
Acetyl-L-carnitine did not prevent taxane-induced peripheral neuropathy and was associated with worse neuropathy scores than placebo at 24 weeks.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.